Market Cap 142.06M P/E - EPS this Y 4.50% Ern Qtrly Grth -
Income -44.73M Forward P/E -3.23 EPS next Y 13.30% 50D Avg Chg -41.00%
Sales 273k PEG -0.24 EPS past 5Y - 200D Avg Chg -34.00%
Dividend N/A Price/Book 2.14 EPS next 5Y 20.40% 52W High Chg -58.00%
Recommedations 1.80 Quick Ratio 7.85 Shares Outst. 48.32M 52W Low Chg 92.00%
Insider Own 0.25% ROA -28.72% Shares Float 39.73M Beta 2.17
Inst Own 77.21% ROE -84.00% Short Shares 0 Price 2.94
Gross Margin - Profit Margin - Avg. Volume 1,016,775 Target Price 5.38
Oper. Margin -15,929.30% Earnings Feb 11 Volume 2,617,010 Change 2.08%
Otonomy, Inc. News
07:30 AM Otonomy to Participate in Three Upcoming Investor Conferences
02/22/21 ROCE Insights For Otonomy
02/22/21 Otonomy stock loses half its value after disappointing trial results of vertigo treatment
02/22/21 Otonomy's OTIVIDEX Fails To Separate From Placebo In Inner Ear Disorder Study
02/22/21 Otonomy Announces Top-Line Results for the Phase 3 Clinical Trial of OTIVIDEX® in Patients with Ménière's Disease
02/17/21 Otonomy Announces Multiple Presentations at Association for Research in Otolaryngology Annual Meeting
02/12/21 Otonomy (OTIC) Q4 2020 Earnings Call Transcript
02/11/21 Otonomy Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
02/11/21 Otonomy, Inc. to Host Earnings Call
02/04/21 Otonomy to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update
02/04/21 Is Otonomy (NASDAQ:OTIC) Weighed On By Its Debt Load?
01/05/21 Otonomy to Participate in the H.C. Wainwright BioConnect 2021 Virtual Conference
12/17/20 Otonomy Reports Positive Top-Line Results from Phase 1/2 Clinical Trial of OTO-413 in Patients with Hearing Loss
12/15/20 Is OTIC A Good Stock To Buy Now?
12/14/20 Otonomy (OTIC) Looks Good: Stock Adds 5% in Session
11/30/20 Otonomy Provides Update on OTIVIDEX® and OTO-313 Programs
11/16/20 Otonomy to Participate in Two Upcoming Investor Conferences
11/06/20 Otonomy, Inc. (NASDAQ:OTIC) Just Reported Third-Quarter Earnings And Analysts Are Lifting Their Estimates
11/04/20 Otonomy (OTIC) Reports Q3 Loss, Misses Revenue Estimates

Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. It also develops OTIVIDEX, a sustained-exposure formulation of the steroid dexamethasone in Phase III clinical trial for the treatment of Ménière's disease; OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase I/II clinical trial to treat tinnitus; and OTO-413, a proprietary formulation of brain-derived neurotrophic factor that is in Phase I/II clinical trial for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. In addition, the company develops OTO-510, a sustained-exposure formulation of small molecule otoprotectant for the prevention of cisplatin-induced hearing loss; and OTO-6XX induces hair cell regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was founded in 2008 and is headquartered in San Diego, California.

OTIC Chatroom

User Image STCKPRO Posted - 13 minutes ago

$OTIC NEW ARTICLE : Otonomy to Participate in Three Upcoming Investor Conferences

User Image cctranscripts Posted - 16 minutes ago

Otonomy to Participate in Three Upcoming Investor Conferences $OTIC

User Image ChartMill Posted - 16 minutes ago

$OTIC: Otonomy to Participate in Three Upcoming Investor Conferences

User Image fla Posted - 17 minutes ago

$OTIC [15s. delayed]: Issued Press Release on February 25, 07:30:00: Otonomy to Participate in Three Upcoming Investor Conferences

User Image Newsfilter Posted - 18 minutes ago

$OTIC Otonomy to Participate in Three Upcoming Investor Conferences

User Image Quantisnow Posted - 18 minutes ago

$OTIC 📑 Otonomy to Participate in Three Upcoming Investor Conferences #majorpharmaceuticals #healthcare

User Image Stock_Titan Posted - 19 minutes ago

$OTIC Otonomy to Participate in Three Upcoming Investor Conferences

User Image MarketBeat Posted - 54 minutes ago

Oppenheimer Lowers Otonomy Q1 2021 Earnings Estimates to ($0.18) EPS (Previously ($0.17)). $OTIC

User Image FinanceRocks Posted - 16 hours ago

$XL If I was XL Management I would love the price to sit here for next 5 days. I am sure Management is smart and knowledgeable. They will release some awesome news after 1 March and it will run and sustain gains. All up from here. P.S I am unfortunately not in it. Because my money is stuck in $CLA $MYOV and $OTIC . Don't like using Margin because I know it can force you to sell at worst possible times but If I ever use Margin it is in this Stock at these prices.

User Image Chamberlain26 Posted - 17 hours ago

$OTIC Buying Mid March 5 buck calls .15

User Image Lfcboy Posted - 17 hours ago

$OTIC still a perfect chance get in now. Going to be a very good swing trade.

User Image Zilla08 Posted - 18 hours ago

$OTIC will bounce near 3 for weeks or so.

User Image Jazmillz Posted - 18 hours ago

$OTIC good time to get in this one imo

User Image Sebool Posted - 19 hours ago

$OTIC pull sold and ran, hard to get them back

User Image NotJustAnotherTwit Posted - 20 hours ago

$OTIC bottom has been found, new life starts here. The journey back to Mordor... err... 5$ has officially begun.

User Image B1B Posted - 21 hours ago

$OTIC $2.78 to $2.85 was the time to cover shorts and go long

User Image Lfcboy Posted - 21 hours ago

$OTIC we only going up from here boysss

User Image Zilla08 Posted - 21 hours ago

$OTIC u Bois Betta hold above 3. Need to rescue lost astronauts at 4

User Image patriotsfan5 Posted - 21 hours ago

$OTIC anyone have an idea as to why the June and September call options are getting decent money? I thought there was no catalyst until 2022

User Image KevWallstreet Posted - 22 hours ago

$OTIC grabbed a starter. “DJ Otonomy Price Target Cut to $5.50/Share From $10.00 by HC Wainwright & Co.”

User Image casper__trade Posted - 23 hours ago

$OTIC Great turn around potential - market have severely overreacted to a drug failing to be passed. Can easily see this returning to $4-4.5 in the near term.

User Image officemaster Posted - 1 day ago

$OTIC can someone tell me what kind of trading that was yesterday?

User Image airplanemode Posted - 1 day ago

$OTIC "We are disappointed by the top-line results" said Chief Executive David Weber. The company's focus now turns to the "strong pipeline," highlighted by the "successful" clinical trial results of its tinnitus and hearing loss treatments, with clinical readouts anticipated in mid-2022. Weber said he expects the company's existing cash balance is enough to to achieve the clinical readouts.

User Image Zilla08 Posted - 1 day ago

$OTIC u Bois holding or what

User Image ManyThanks212 Posted - 1 day ago

$OTIC bounce

User Image Lfcboy Posted - 1 day ago

$OTIC green days coming soon! I’m holding till this goes back to the norm.

User Image B1B Posted - 1 day ago

Sell sell sell $OTIC 🔥

User Image Sebool Posted - 1 day ago

$OTIC I can’t hear you lol

User Image FinanceRocks Posted - 1 day ago

$WKHS Guys have my Condolences. Been through exact same shit/ loss yesterday in $OTIC . Know your pain. Be strong.

User Image lisah93559 Posted - 1 day ago